This database contains 193 studies, archived under the term: "results"
Click here to filter this large number of results.
Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial
Meeuwsen, Els J.,
Melis, René J. F.,
Van Der Aa, Geert C. H. M.,
Golüke-Willemse, Gertie A. M.,
De Leest, Benoit J. M.,
Van Raak, Frank H. J. M.,
Schölzel-Dorenbos, Carla J M,
Verheijen, Desiree C. M.,
Verhey, Frans R.J.,
Visser, Marieke C.,
Wolfs, Claire A.,
Adang, Eddy M. M.,
Olde Rikkert, Marcel G. M.
Objective: To examine the effectiveness of post-diagnosis dementia treatment and coordination of care by memory clinics compared with general practitioners.; Design: Multicentre randomised controlled trial.; Setting: Nine memory clinics and 159 general practitioners in the Netherlands.; Participants: 175 patients with a new diagnosis of mild to moderate dementia living in the community and their informal […]
Predictors of acceptance of offered care management intervention services in a quality improvement trial for dementia
Kaisey, Marwa,
Mittman, Brian,
Pearson, Marjorie,
Connor, Karen I.,
Chodosh, Joshua,
Vassar, Stefanie D.,
Nguyen, France T.,
Vickrey, Barbara G.
Objective: Care management approaches have been proven to improve outcomes for patients with dementia and their family caregivers (dyads). However, acceptance of services in these programs is incomplete, impacting effectiveness. Acceptance may be related to dyad as well as healthcare system characteristics, but knowledge about factors associated with program acceptance is lacking. This study investigates […]
Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia
Herrmann, Nathan,
Black, Sandra E.,
Chow, Tiffany,
Cappell, Jaclyn,
Tang-Wai, David F.,
Lanctôt, Krista L.
Objectives: The purposes of this study were first, to evaluate the effectiveness of citalopram in treating behavioral disturbances in frontotemporal dementia (FTD) subjects and second, to determine whether an association exists between serotonergic function, as determined by a neuroendocrine challenge, and treatment response.; Design: Single-dose citalopram (30 mg per os) challenge followed by a 6-week […]
Relapse risk after discontinuation of risperidone in Alzheimer’s disease
Devanand, D. P.,
Mintzer, Jacobo,
Schultz, Susan K.,
Andrews, Howard F.,
Sultzer, David L.,
de la Pena, Danilo,
Gupta, Sanjay,
Colon, Sylvia,
Schimming, Corbett,
Pelton, Gregory H.,
Levin, Bruce
Background: Among patients with Alzheimer’s disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.; Methods: Patients with Alzheimer’s disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a […]
A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects
Dockens, Randy,
Wang, Jun-Sheng,
Castaneda, Lorna,
Sverdlov, Oleksandr,
Huang, Shu-Pang,
Slemmon, Randy,
Gu, Huidong,
Wong, Oi,
Li, Hewei,
Berman, Robert M.,
Smith, Christina,
Albright, Charles F.,
Tong, Gary
Background and Objectives: Avagacestat is an orally active γ-secretase inhibitor that selectively inhibits amyloid β (Aβ) synthesis in cell culture and animal models. The objective of the current study was to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of avagacestat over 28 days in healthy young men and elderly men and women […]